Anti-Inflammatory Compounds

Celgene is developing novel orally available small molecules that inhibit the production of multiple proinflammatory mediators including interleukin-2 (IL-2), IL-12, interferon-gamma, TNF-alpha, leukotrienes, and nitric oxide synthase.

Our lead investigational drug, CC-10004 (apremilast), is being studied in Phase II clinical trials for the treatment of psoriasis and other chronic inflammatory diseases. We successfully completed our early stage studies and found CC-10004 to be safe and well-tolerated. CC-10004, an oral TNF antagonist and anti-inflammatory agent, has demonstrated significant activity and an excellent side effect profile in a placebo controlled proof-of-mechanism trial in psoriasis. With the initiation of additional multi-center trials, we are advancing the clinical development of CC-10004.

CC-11050 is currently in Phase I clinical trials for chronic inflammatory diseases.

The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.